|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
UA71971C2
(en)
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
WO2001004111A1
(en)
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
|
AU2001249865A1
(en)
|
2000-04-18 |
2001-10-30 |
Agouron Pharmaceuticals, Inc. |
Pyrazoles for inhibiting protein kinase
|
|
MY143465A
(en)
|
2001-01-05 |
2011-05-13 |
Pfizer |
Antibodies to insulin-like growth factor i receptor
|
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
|
AR039067A1
(en)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
|
EP1481077B1
(en)
*
|
2001-12-06 |
2009-11-04 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
AU2002363960B2
(en)
|
2001-12-06 |
2008-07-10 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
|
AU2003225933A1
(en)
*
|
2002-03-22 |
2003-10-13 |
Cellular Genomics, Inc. |
AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
MXPA05006676A
(en)
|
2002-12-19 |
2005-08-16 |
Pfizer |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases.
|
|
DK1625121T3
(en)
|
2002-12-20 |
2010-05-10 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
|
ES2314444T3
(en)
|
2003-08-29 |
2009-03-16 |
Pfizer Inc. |
TIENOPIRIDINE-PHENYLACETAMIN AND ITS USEFUL DERIVATIVES AS NEW ANTIANGIOGEN AGENTS.
|
|
AR045563A1
(en)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
|
EA013678B1
(en)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
ES2372217T3
(en)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING THE GENE OF PDGFRA, KIT OR KDR AS A GENETIC MARKER.
|
|
MY146474A
(en)
|
2006-11-06 |
2012-08-15 |
Supergen Inc |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
|
PL2185574T3
(en)
|
2007-09-07 |
2013-09-30 |
Agensys Inc |
Antibodies and related molecules that bind to 24p4c12 proteins
|
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
|
JP5836125B2
(en)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof
|
|
AU2009308675A1
(en)
|
2008-10-31 |
2010-05-06 |
Genentech, Inc. |
Pyrazolopyrimidine JAK inhibitor compounds and methods
|
|
MX2011004824A
(en)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
Use of catecholic butane derivatives in cancer therapy.
|
|
SG172857A1
(en)
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
JP2012519281A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010107968A1
(en)
|
2009-03-18 |
2010-09-23 |
Osi Pharmaceuticals, Inc. |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
PE20120539A1
(en)
|
2009-03-20 |
2012-05-12 |
Genentech Inc |
ANTI-HER BIESPECIFIC ANTIBODIES
|
|
UA110324C2
(en)
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
|
CA2780319A1
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
RU2012132278A
(en)
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
TRICYCLIC HETEROCYCLIC COMPOUNDS CONTAINING THEIR COMPOSITIONS AND WAYS OF THEIR APPLICATION
|
|
MX343383B
(en)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl }-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one.
|
|
ES2519348T3
(en)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Neurregulin antagonists and their use in cancer treatment
|
|
BR112012023382A2
(en)
|
2010-03-17 |
2018-05-15 |
F Hoffmann La Roche Ag T |
imidazopyridine compounds, compositions and methods of use.
|
|
MX2012011887A
(en)
|
2010-04-16 |
2012-11-30 |
Genentech Inc |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy.
|
|
CN104689314B
(en)
|
2010-06-16 |
2018-02-02 |
高等教育联邦***-匹兹堡大学 |
Antibody of endoplasmin and application thereof
|
|
EP2612151B1
(en)
|
2010-08-31 |
2017-08-09 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
EP2616072A1
(en)
|
2010-09-15 |
2013-07-24 |
F.Hoffmann-La Roche Ag |
Azabenzothiazole compounds, compositions and methods of use
|
|
EP2640722B1
(en)
*
|
2010-11-19 |
2015-11-04 |
F.Hoffmann-La Roche Ag |
Pyrazolopyridines and their use as tyk2 inhibitors
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
CA2830972C
(en)
|
2011-04-19 |
2018-11-20 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
JP2014519813A
(en)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
PT3409278T
(en)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Heterocyclic protein kinase inhibitors
|
|
RU2014105624A
(en)
|
2011-08-12 |
2015-09-20 |
Ф. Хоффманн-Ля Рош Аг |
COMPOUNDS OF INDAZOL, METHOD OF THEIR APPLICATION AND PHARMACEUTICAL COMPOSITION
|
|
MX2014001766A
(en)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Neuregulin antibodies and uses thereof.
|
|
MX2014002436A
(en)
|
2011-08-31 |
2014-05-27 |
Genentech Inc |
Diagnostic markers.
|
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
CN104066851A
(en)
|
2011-09-30 |
2014-09-24 |
基因泰克公司 |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells
|
|
AU2011378675B2
(en)
|
2011-10-04 |
2017-10-05 |
Epsilogen Ltd |
IgE anti -HMW-MAA antibody
|
|
BR112014011115A2
(en)
|
2011-11-08 |
2017-06-13 |
Pfizer |
Methods for treating inflammatory disorders using anti-csf antibodies
|
|
MX2014006529A
(en)
|
2011-11-30 |
2014-11-25 |
Genentech Inc |
Erbb3 mutations in cancer.
|
|
AR090263A1
(en)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
|
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
EP2909181B1
(en)
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
JP2016509045A
(en)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
How to treat cancer and prevent drug resistance
|
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
RU2015143517A
(en)
|
2013-03-13 |
2017-04-19 |
Дженентек, Инк. |
Pyrazole-containing compounds and their use
|
|
KR102334260B1
(en)
|
2013-03-14 |
2021-12-02 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 and alk2 inhibitors and methods for their use
|
|
CN105246508A
(en)
|
2013-03-14 |
2016-01-13 |
基因泰克公司 |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
KR20150127216A
(en)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Methods of treating cancer and preventing cancer drug resistance
|
|
US20160143910A1
(en)
|
2013-03-15 |
2016-05-26 |
Constellation Pharmaceuticals, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
TW201605896A
(en)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
GITR antigen binding proteins
|
|
CN105611933B
(en)
|
2013-09-05 |
2019-01-25 |
基因泰克公司 |
Anti-proliferate compound
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
TW201605857A
(en)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Therapeutic inhibitors of CDK8 and uses thereof
|
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
|
EP3057615B1
(en)
|
2013-10-18 |
2021-02-24 |
F.Hoffmann-La Roche Ag |
Anti-rspo antibodies and methods of use
|
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
AU2014364587B9
(en)
|
2013-12-17 |
2023-02-16 |
Genentech, Inc. |
Methods of treating cancers using PD-1 axis binding antagonists and taxanes
|
|
RU2016141385A
(en)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
|
|
KR20160145624A
(en)
|
2014-03-31 |
2016-12-20 |
제넨테크, 인크. |
Anti-ox40 antibodies and methods of use
|
|
CA2943834A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
US9346815B2
(en)
|
2014-05-23 |
2016-05-24 |
Genentech, Inc. |
5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
|
|
JP6811706B2
(en)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Human monoclonal antibodies against EPHA4 and their use
|
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN107073125A
(en)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
CBP/EP300 and BET inhibitor is used for the purposes for the treatment of cancer
|
|
CN107912040B
(en)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
|
BR112017009151A2
(en)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
Assays for Detecting Immune T-Cell Subgroups and Methods of Using Them
|
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MA40943A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MA40940A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
|
RU2710735C2
(en)
|
2014-12-23 |
2020-01-10 |
Дженентек, Инк. |
Compositions and methods of treating and diagnosing cancer-resistant cancer
|
|
JP6900314B2
(en)
|
2014-12-24 |
2021-07-07 |
ジェネンテック， インコーポレイテッド |
Treatment, diagnosis, and prognosis of bladder cancer
|
|
CN107208138A
(en)
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
For cancer prognosis and the method and composition for the treatment of
|
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA41598A
(en)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
|
|
KR20180002653A
(en)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
Antigen binding complexes having an agonistic activity activity and methods of use
|
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
MX2017013956A
(en)
|
2015-05-01 |
2018-09-05 |
Cocrystal Pharma Inc |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer.
|
|
LT3294770T
(en)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
DK3298021T3
(en)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
ALVOCIDIB PRODRUGS THAT HAVE INCREASED BIOTAILABILITY
|
|
JP7144935B2
(en)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
Therapeutic and diagnostic methods for cancer
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
WO2016205320A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
EP3331510A4
(en)
|
2015-08-03 |
2019-04-03 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
PL3341376T3
(en)
|
2015-08-26 |
2021-08-02 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
HRP20220227T1
(en)
|
2015-12-16 |
2022-04-29 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
|
BR112018011029A2
(en)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
methods for treating or delaying cancer progression and improving immune function in a cancer individual, uses of a binding antagonist and a bispecific antibody, compositions and kits
|
|
KR20180119632A
(en)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
Treatment and Diagnosis Methods for Cancer
|
|
UA126115C2
(en)
|
2016-03-08 |
2022-08-17 |
Янссен Байотек, Інк. |
Gitr antibodies, methods, and uses
|
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
EP3443114A1
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
JP2019515670A
(en)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
Methods for monitoring and treating cancer
|
|
JP7014736B2
(en)
|
2016-05-24 |
2022-02-01 |
ジェネンテック， インコーポレイテッド |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
EP4067347A1
(en)
|
2016-05-24 |
2022-10-05 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
|
|
JP2019527037A
(en)
|
2016-06-08 |
2019-09-26 |
ジェネンテック， インコーポレイテッド |
Diagnosis and treatment methods for cancer
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP2019535250A
(en)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
Anti-MIC antibody and method of use
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
|
CN116606261A
(en)
|
2016-12-22 |
2023-08-18 |
美国安进公司 |
KRAS G12C inhibitors and methods of use thereof
|
|
MX2019010295A
(en)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Diagnostic and therapeutic methods for cancer.
|
|
CN110505883A
(en)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
Proleulzin immunoconjugates used in method for treating cancer, CD40 agonist, and optionally PD-1 axis binding antagonists
|
|
JP7256757B2
(en)
|
2017-05-22 |
2023-04-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
Therapeutic compounds and compositions, and methods of their use
|
|
JOP20190272A1
(en)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP2020530297A
(en)
|
2017-08-11 |
2020-10-22 |
ジェネンテック， インコーポレイテッド |
Anti-CD8 antibody and its use
|
|
CN116003405A
(en)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Inhibitors of KRAS G12C and methods of use thereof
|
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
JP7196160B2
(en)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
KR20200075860A
(en)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
How to diagnose and treat cancer
|
|
TW202000702A
(en)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MA52496A
(en)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
|
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
JP2021524744A
(en)
|
2018-05-21 |
2021-09-16 |
ナノストリング テクノロジーズ，インコーポレイティド |
Molecular gene signature and how to use it
|
|
MA52765A
(en)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
|
|
EP3802537A1
(en)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
KR20210063330A
(en)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
Methods of treatment and diagnosis for bladder cancer
|
|
JP2022500638A
(en)
|
2018-09-21 |
2022-01-04 |
ジェネンテック， インコーポレイテッド |
Diagnostic methods for triple-negative breast cancer
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
KR20210079311A
(en)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
Diagnosis and treatment methods for sarcoma renal cancer
|
|
JP2020090482A
(en)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
|
JP7377679B2
(en)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
|
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
WO2020117988A1
(en)
|
2018-12-04 |
2020-06-11 |
Tolero Pharmaceuticals, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
EP3897852A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Kif18a inhibitors
|
|
AU2019403488A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
AU2019401495A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
|
JP2022519649A
(en)
|
2019-02-08 |
2022-03-24 |
ジェネンテック， インコーポレイテッド |
How to diagnose and treat cancer
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
CN113710706A
(en)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
Administration for anti-TIGIT antibody and anti-CD 20 antibody or anti-CD 38 antibody treatment
|
|
US20220146495A1
(en)
|
2019-02-27 |
2022-05-12 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
SG11202109036WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
|
CA3130083A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
JP2022519923A
(en)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
Compositions comprising a PKM2 modulator and methods of treatment using it
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
|
US20220289724A1
(en)
|
2019-08-02 |
2022-09-15 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
MX2022001302A
(en)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Pyridine derivatives as kif18a inhibitors.
|
|
PE20221449A1
(en)
|
2019-09-04 |
2022-09-21 |
Genentech Inc |
CD8 BINDING AGENTS AND USES THEREOF
|
|
CN114555116A
(en)
|
2019-09-27 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
Administration for anti-TIGIT and anti-PD-L1 antagonist antibody therapy
|
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
|
EP4054720A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
KR20220109408A
(en)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
RAS inhibitors
|
|
CN115873067A
(en)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
RAS inhibitors
|
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
MX2022005775A
(en)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Therapeutic compounds and methods of use.
|
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
MX2022005726A
(en)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Improved synthesis of kras g12c inhibitor compound.
|
|
CN114980976A
(en)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
Covalent RAS inhibitors and uses thereof
|
|
CR20230210A
(en)
|
2019-12-13 |
2023-06-14 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
BR112022010086A2
(en)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
SHP2 INHIBITOR DOSAGE AND CANCER TREATMENT METHODS
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
CN115315256A
(en)
|
2020-01-27 |
2022-11-08 |
基因泰克公司 |
Methods of treating cancer with anti-TIGIT antagonist antibodies
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
CN115885050A
(en)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
BR112022025801A2
(en)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
METHODS FOR TREATING A PATIENT AND FOR TREATING A PATIENT WITH ADVANCED ESCC, KIT, ANTIBODY, USE OF AN ANTIBODY, AND USE OF A BINDING ANTAGONIST
|
|
AU2021293228A1
(en)
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN116568824A
(en)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
Method for diagnosing and treating lymphoma
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
PE20231207A1
(en)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
CR20230382A
(en)
|
2021-02-12 |
2023-09-06 |
Hoffmann La Roche |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
PE20240088A1
(en)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AR125787A1
(en)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
TW202313633A
(en)
|
2021-05-25 |
2023-04-01 |
美商伊瑞斯卡公司 |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202321261A
(en)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
Selective kras inhibitors
|
|
AR127308A1
(en)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
TW202340212A
(en)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
|
TW202340214A
(en)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|